"Clinical appraisal of Pluvicto in the Phase III VISION trial successfully showed Pluvicto improving imaging-based ...

The expression of PSMA prior to treatment with Pluvicto™ can be determined using whole body PSMA-directed imaging, allowing for personalization of treatment so that the best course of therapy might be ...

After a median follow-up of 20.9 months, patients on Pluvicto had radiographic progression-free survival (PFS) of 8.7 months, compared to 3.4 months in the control group, while overall survival ...

The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.